# Safety, Reactogenicity and Immunogenicity Study of ReCOV

> **NCT04818801** · EARLY_PHASE1 · COMPLETED · sponsor: **Jiangsu Rec-Biotechnology Co., Ltd.** · enrollment: 100 (actual)

## Conditions studied

- Covid19

## Interventions

- **BIOLOGICAL:** Recombinant two-component COVID-19 vaccine (CHO cell)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04818801
- **Lead sponsor:** Jiangsu Rec-Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-18
- **Primary completion:** 2022-05-05
- **Final completion:** 2022-05-05
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2022-09-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04818801

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04818801, "Safety, Reactogenicity and Immunogenicity Study of ReCOV". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04818801. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*